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Abstract
Introduction: The aim was to investigate the prevalence of endotoxemia in children admitted to pediatric
intensive care unit (PICU), and its association with disease severity and outcome.
Methods: We conducted a prospective, observational cohort study of children admitted to PICU at St. Mary’s
Hospital, London over a 6-month period. One hundred consecutive patients were recruited. Demographic and
clinical data were collected. Severity of illness was assessed by the pediatric index of mortality 2 (PIM2) score. The
pediatric logistic organ dysfunction (PELOD) score was performed daily for the first 4 days. Patients were
categorized according to primary reason for PICU admission. Blood samples were taken within 24 hours of
admission and endotoxemia was measured using the endotoxin activity assay (EAA). Patients were stratified
according to EAA level (high, EAA > 0.4, low, EAA < 0.4) and categorized as septic, post-surgical, respiratory or
other. Data were analyzed using appropriate non-parametric tests.
Results: EAA level was significantly lower in PICU controls versus other PICU admissions (P = 0.01). Fifty-five
children had endotoxemia on admission. Forty-one (75%) of these were eventually diagnosed with an infectious
cause of admission. Nine children without infection had elevated EAA on admission. An infectious cause of
admission was significantly associated with endotoxemia (P < 0.005). Of 15 children with gram-negative infection,
only 9 (60%) had endotoxemia on admission. Endotoxemia on admission was not associated with shock or death.
However, there was a tendency for increased PELOD score and length of stay in endotoxemic children.
Conclusions: Endotoxemia is common in children admitted to intensive care. Understanding the implications of
endotoxemia and potential anti-endotoxin strategies may have the potential to reduce severity of illness and
length of PICU stay in critically ill children.
Introduction
Sepsis is a major cause of admission to pediatric inten-
sive care units (PICUs) and causes significant morbidity
and mortality in children. A recent study from the US
estimated that the incidence of pediatric severe sepsis is
0.56 cases per 1,000 population and that severe sepsis
has an overall hospital mortality rate of 10.3% and
accounts for 7% of all deaths in children [1].
In 2009, there were nearly 17,000 admissions to PICUs
in the UK. Of these, nearly 9,000 (53%) were unplanned
medical admissions for conditions such as sepsis, pneu-
monia, bronchiolitis, and respiratory failure (Pediatric
I n t e n s i v eC a r eA u d i tN e t w o r k[ P I C A N E T ]A n n u a l
Report 2009) [2]. The unadjusted case fatality rate for
children admitted to PICUs in the UK is 4.1% and these
children account for over 100,000 bed days. A recent
audit of referrals of children with sepsis to PICUs in the
UK found that 17% of these children died [3].
The earliest events in the pathogenesis of sepsis are
interactions of pathogen-related antigens (for example,
endotoxin (lipopolysaccharide, LPS) and peptidoglycan)
with cell surface pattern recognition receptors such as
the Toll-like receptors 4 and 2, respectively [4]. The
interaction of LPS with its receptors and the subsequent
cellular responses have been well described and are
pivotal processes in the inflammatory response leading
to the manifestations of sepsis [5].
Measuring the concentration of LPS in human disease
has been notoriously difficult. The most commonly used
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(LAL) assay, is based on the ability of endotoxin to
induce coagulation of hemolymph in the horseshoe
crab, Limulus polyphemus [6]. The utility of this assay
has been limited because of circulating inhibitors of the
coagulation reaction. In addition, the assay is not speci-
fic for endotoxin.
A novel endotoxin assay, which is simpler and more
accurate than the LAL assay, was recently described [7].
This endotoxin activity assay (EAA) detects LPS in
whole blood by the use of neutrophil-dependent chemi-
luminescence. This assay was used in a study of criti-
cally ill adults, in which an association between
endotoxemia with infection and an increased risk of
adverse outcome was demonstrated [8]. Because of the
link between endotoxin and inflammation, we sought to
define the prevalence of endotoxemia in critically ill
children and determine the association of endotoxemia
with infection, severity of illness, and outcome.
Materials and methods
We undertook a prospective observational cohort study
of critically ill children admitted to the PICU at St
Mary’s Hospital, London, over the course of a 6-month
period (January to June 2007). The unit does not admit
cardiac-surgical or neurosurgical patients. Informed con-
sent was obtained from parents or carers. The study was
approved by the local research ethics committee.
Demographic and clinical data were collected on
admission to the PICU. Patients were categorized by
their primary reason for admission: respiratory failure
(that is, acute viral bronchiolitis, croup, asthma, or
pneumonia), neurological failure (that is, meningo-ence-
phailitis or status epilepticus), sepsis, cardiac (that is,
myocarditis or arrhythmia), surgical, or other (that is,
trauma or cardiac arrest).
We defined a PICU control group as children who
were electively admitted to the PICU for post-operative
care. They were all electively ventilated but had no
other organ failure on admission.
Conditions were diagnosed as sepsis or septic shock
(or both) according to the criteria of Goldstein and col-
leagues [9]. Infection was diagnosed with standard
microbiological techniques.
Severity of illness was assessed by the pediatric index
of mortality 2 (PIM2) score [10], and the pediatric logis-
tic organ dysfunction (PELOD) score [11] was per-
formed daily for the first 4 days (as 4 days was the
mean length of stay, or LOS).
Chemiluminescent assay for endotoxin
All patients had a single measurement of endotoxin
activity (EA) in whole blood within 24 hours of PICU
admission, as described previously [7]. Whole blood
samples (2 mL) were collected into ethylenediaminete-
traacetic acid (EDTA) vacutainer tubes. Samples of 0.5
mL of whole blood in duplicate were immediately incu-
bated with saturating concentrations of a murine IgM
monoclonal antibody against the lipid A of Escherichia
coli J5. This antibody is broadly cross-reactive against
Gram-negative bacteria but does not cross-react with
Gram-positive bacteria. Any LPS present in the blood
complexes with the anti-LPS antibody. This complex
primes the patient’s neutrophils for an augmented
response to stimulation with zymosan. The resulting
respiratory burst activity is detected as light release from
the lumiphor luminol by using a chemiluminometer
(Autolumat LB953; EG&G Berthold, Bad Wildbad/Ger-
many). By measuring basal (no antibody) and maximally
stimulated (4,600 pg/mL LPS) responses in the same
blood sample, the EA of the test specimen is calculated
by integrating chemiluminescence over time. Levels are
expressed as EA units and represent the mean of dupli-
cate determinations from the same sample. An EA level
of greater than 0.4 is approximately equivalent to an
endotoxin concentration of 25 to 50 pg/mL E. coli 055:B5
LPS.
As the EAA requires adequate numbers of patient
neutrophils to provide the respiratory burst for the assay
readout, we excluded patients who had an absolute neu-
tropenia of less than 0.1 × 10
6/cm
3. For the purposes of
this study, a cutoff level of 0.4 EA units, as defined pre-
viously [7], was used to determine the presence of endo-
toxemia (that is, ≤0.4 negative, > 0.4 EA present).
Statistics
Data were non-parametric and are presented as median
± interquartile range (IQR). The results were analyzed
by using GraphPad Prism (GraphPad Software, Inc., La
Jolla, CA, USA). The Mann-Whitney U test was used to
compare groups of data, and the Kruskal-Wallis test was
used if there were more than two groups of data. The
chi-square test was used to compare proportions.
Results
One hundred four consecutive admissions were asked to
participate in the study but four of them refused. No
children were excluded; therefore, 100 patients were
recruited for the study. Their demographics are shown
in Table 1. Ten children (10%) died and 90 were dis-
charged alive from the PICU. The mean LOS for survi-
vors was 7.1 days (median of 5 days and range of 1 to
57). There were 9 children in the control group, 48 in
the respiratory group, 18 in the sepsis group, and 25 in
the ‘other’ group. The control group consisted of two
children who had tonsillectomy and adenoidectomy for
obstructive sleep apnea, three children who had a Nis-
sen fundoplication and gastrostomy, one child who had
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had an esophageal dilatation, one child who had a resec-
tion of a colonic duplication cyst, and one child who
had a partial nephrectomy. None suffered periods of
intra-operative hypotension or needed prolonged post-
operative ventilation.
EAA level was significantly lower in the control group
(0.16, IQR 0.11 to 0.37) compared with the respiratory
(0.48, IQR 0.34 to 0.74), sepsis (0.55, IQR 0.4 to 0.7),
and other (0.37, IQR 0.25 to 0.59) groups (P = 0.01,
Kruskal-Wallis test) (Figure 1).
Fifty-five children had endotoxemia on admission to the
PICU. Only two of these were in the control group (one
child underwent an elective Nissen fundoplication and
had extensive bowel manipulation during surgery, and the
other child underwent an adenotonsillectomy). Of these
55 children, 41 (75%) were eventually given a diagnosis of
an infection-related cause of admission (Table 2).
Seventeen children were bacteremic on admission. Fif-
teen children had Gram-negative infection as the cause
of admission, and only nine (60%) of them were endo-
toxemic on admission. Of the 15 children with Gram-
negative infection, only 5 had Gram-negative bacteremia
(all meningococcus serogroup B). Only 3 of the 5 chil-
dren with meningococcal bacteremia had endotoxemia
detected on admission.
Sixty-two children were given a diagnosis of an infec-
tion-related cause of admission, and 41 (66%) of them
had endotoxemia and 14 of 38 children (37%) had a
non-infectious cause of admission (P = 0.0043, chi-
square test). Seventy-five percent of children with
respiratory failure of any cause had endotoxemia on
admission to the PICU.
All children admitted to our PICU with a suspicion of
infection are treated with a standard regimen of anti-
microbials, consisting of a third-generation cephalos-
porin (usually ceftriaxone) with or without gentamicin if
there is a suspicion of pseudomonas infection (such as
patients with chronic lung disease). There was no clear
correlation between anti-microbial use and endotoxemia
(data not shown).
T h ep r e s e n c eo fe n d o t o x e m i ao na d m i s s i o nt ot h e
PICU was not significantly associated with shock or
death. Twenty-two of 34 children (64%) who had shock
at PICU admission had endotoxemia compared with 35
out of 66 (53%) without shock (P =n o ts i g n i f i c a n t ,c h i -
square test). Seven of the 10 children (70%) who died
had endotoxemia on admission compared with 48 out
of 90 survivors (53%) (P = not significant, chi-square
test). Daily PELOD score, PIM2 score on admission, and
LOS in survivors were not significantly different
between the groups with and without endotoxemia on
admission, although there was a tendency for increased
PELOD score and LOS in the group with endotoxemia
(Table 3).
Discussion
Our study shows that endotoxemia is common in a het-
erogeneous population of critically ill children. Although
there was no clear correlation with severity of illness or
the presence of shock, there was a tendency toward
Table 1 Demographic data
Number
Total population recruited 100
Age in months
Median 33.8
Range 0-180
Males 63
Diagnosis
Respiratory
a 48
Sepsis 18
Other
b 25
Control
c 9
Shock on admission 34
Died before discharge 10
aIncludes eight patients with respiratory syncytial virus bronchiolitis.
bIncludes
seven patients with primary neurological failure and four patients with
primary cardiac failure.
cPost-operative elective admission. Patients may fall
into more than one category.
Figure 1 Endotoxin activity assay (EAA) level related to clinical
classification. For a statistical analysis, see the ‘Statistics’ section.
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sistent with a recent study in adult surgical intensive
care patients, which showed an association between
endotoxemia and LOS in the intensive care unit [12].
Despite the high prevalence of endotoxemia found in
our study, only 15 children had a Gram-negative infec-
tion, a scenario classically associated with endotoxemia.
In addition, only 9 of 15 children with documented
Gram-negative infection had endotoxemia. This may
reflect the timing of the assay in relation to admission
and treatment. It has previously been noted that endo-
toxin level in blood declines rapidly following appropri-
ate anti-microbial therapy [13]. We did not record the
timing of performance of the EAA in relation to the
start of anti-microbial therapy, but 75% of the samples
were taken within 12 hours of admission to the PICU.
The commonest cause of PICU admission in our
study was respiratory failure that was usually due to
viral lower respiratory tract infection. The majority
(75%) of children with a respiratory tract infection had
endotoxemia on admission despite having low severity-
of-illness scores and good outcome. Several studies have
documented high levels of endotoxin in the lung and
blood of patients with respiratory infection as well as
those on artificial ventilation. Pulmonary-to-systemic
translocation of LPS has been demonstrated in non-pro-
tective ventilation strategy studies in experimental ani-
mals [14], and an association between ventilator-
induced lung injury, ventilator-associated pneumonia,
and systemic LPS and cytokine levels has been reported
[15]. Although the lung has no endogenous microflora
that could provide a source of LPS, it is likely that bac-
terial colonization of the airway or lung may be a poten-
tial source of LPS that can translocate systemically
following mechanical ventilation. The high prevalence of
endotoxemia in our patients seems to confirm this.
The gut provides a second and major potential source
of systemic LPS. The indigenous flora of the gastroin-
testinal tract contains large amounts of endotoxin, and
translocation of both endotoxin and viable bacteria from
the gut has been demonstrated in animal models and in
human illness associated with splanchnic hypoperfusion
[16,17]. Consistent with this, we observed that endotox-
emia was more common in critical illness compared
with control children. In addition, patients who had
endotoxemia on admission appeared to be a sicker
population, as reflected by longer LOS and a trend
toward higher PELOD scores. Thus, the presence of
endotoxemia on admission may identify a high-risk sub-
population of critically ill children.
The chemiluminescent assay used in our study is both
sensitive and specific for endotoxin and can be per-
formed in less than 1 hour, permitting the rapid detec-
tion of endotoxin in fresh whole blood. However, it uses
the patient’s own neutrophils as a readout system and
so presents inherent limitations; in particular, it is not
possible to store specimens for later assay; measure-
ments must be performed within 3 hours of obtaining
the sample. Because of the requirement for neutrophils,
the assay is not reliable in patients with an absolute
neutrophil count of less than 0.1 × 10
6/cm
3. The assay
relies on neutrophil chemiluminescence in response to
IgM anti-LPS antibody and LPS. However, the pre-acti-
vation state is accounted for by correcting for baseline
chemiluminescence in the EAA. In addition, the assay
detects exposed lipid A in the endotoxin molecule and
so may not reflect endotoxin bioactivity in vivo.H o w -
ever, the availability of a relatively simple bedside assay
Table 2 Infectious causes of admission (n = 62)
Number
Viral
Adenovirus 3
Influenza A 2
HHV6 1
Metapneumovirus 2
Parainfluenza 1 1
RSV 8
Varicella 2
Bacterial
Staphylococcus aureus 8
Group A Streptococcus 4
Group B Streptococcus 2
Haemophilus influenzae 3
Klebsiella spp. 1
Meningococcus 6
Pneumococcus 8
Pseudomonas 4
Salmonella spp. 1
Other
PCP 2
Malaria 1
Aspergillus 1
Candida 2
HHV6, human herpes virus 6; PCP, pneumocystis jirovecii pneumonia; RSV,
respiratory syncytial virus.
Table 3 Severity of illness
EAA ≤0.4 EAA > 0.4 Mann-
Whitney
PIM score, median (IQR) 5% (1.5%-
13%)
6% (2%-
20%)
P = 0.35
PELOD score, median (IQR) 1.7 (1.15-
20.8)
16.2 (1.3-
20.8)
P = 0.31
LOS of survivors, median
(IQR)
4 (2-7) 5 (4-8) P = 0.05
EAA, endotoxin activity assay; IQR, interquartile range; LOS, length of stay
(days); PELOD, pediatric logistic organ dysfunction; PIM, pediatric index of
mortality.
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lation of critically ill patients who may benefit from
adjunctive therapy.
We did not correlate the EAA with the best-known
endotoxin assay, the LAL assay. The LAL assay has
been widely used to detect endotoxin contamination of
drugs and fluids; however, its utility in biological sam-
ples has been limited because of circulating inhibitors of
the coagulation reaction. In addition, other microbial
products, notably from fungi, can activate the LAL reac-
tion, so the assay is not specific for endotoxin [18]. Stu-
dies comparing EAA and LAL show considerable
variability in the prevalence of endotoxemia or its asso-
ciation with Gram-negative infection, and the EAA is
able to detect endotoxemia associated with Gram-nega-
tive infection from any source, a diagnosis of sepsis, and
an elevated white blood cell count; no such correlations
were found when samples were assayed using the LAL
method [19].
Antibiotics can accelerate endotoxin release and may
result in false-negative blood cultures [20]. We did not
correlate endotoxemia with type and duration of anti-
microbial therapy. However, most patients would have
been treated with our typical empiric anti-microbial regi-
men, which consisted of a third-generation cephalosporin,
with additional gentamicin in certain cases, such as those
with specific risk factors for pseudomonas infection.
Whether the increased LOS and possible increased
severity of illness associated with endotoxemia might be
r e d u c e db ys p e c i f i cm e a s u r e st on e u t r a l i z ee n d o t o x i n
needs to be studied further, but the hypothesis remains
attractive. High levels of endotoxin have been associated
with increased severity of illness in meningococcal disease
[13], and studies of anti-endotoxin therapy in human sep-
sis suggest that the greatest potential benefit occurs in
patients in whom endotoxemia is likely to be present [21].
I n f e r e n c e sf r o mt h ep r e s e n ts t u d ya r el i m i t e db yi t s
observational nature and the relatively small number of
patients in each disease category. In addition, the timing
of the assay may have ‘missed’ the peak of endotoxemia
in those patients in whom anti-microbial therapy had
been initiated prior to PICU admission. In addition,
intrinsic anti-EA (such as endotoxin antibodies) and
lipoproteins may quench EA.
Conclusions
The demonstration of significant endotoxemia in a high
proportion of children admitted to the PICU for any
one of several pathologies suggests an important interac-
tion between critical illness and inflammation induced
or augmented by intrinsically derived endotoxin. It is
possible that this endotoxemia contributes to severity of
illness and outcome. The hypothesis that LPS contri-
butes to disease severity in critical illness requires
further exploration. Our study suggests that endotoxe-
mia in critically ill children is common and can be
detected with a simple bedside test. The use of anti-
endotoxin agents potentially may have a role in the
treatment of critical illness of all causes in children, and
this should be the subject of future studies.
Key messages
￿ Children with critical illness of any cause are likely
to have endotoxemia.
￿ Endotoxemia can be accurately detected by a sim-
ple bedside test.
￿ Endotoxemia may be associated with increased
severity of illness and length of stay in the pediatric
intensive care unit.
￿ It is likely that the source of endotoxin in these
children is their own gut or lung.
￿ If the findings of this study are confirmed in larger
studies, anti-endotoxin therapies may be a logical
adjunct to the treatment of pediatric critical illness.
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